Top 8 Nephrology Updates in November 2025: IgAN Breakthroughs, FDA Approvals & More! (2026)

8 Nephrology Headlines You Missed in November 2025: Key Insights from the Month

The nephrology field witnessed significant advancements in November 2025, with groundbreaking discoveries in IgA nephropathy (IgAN), kidney transplantation, and chronic kidney disease (CKD). Here's a curated list of the most impactful headlines from the month, offering a glimpse into the evolving landscape of kidney care:

1. FDA Approves Sibeprenlimab for IgAN: The US Food and Drug Administration (FDA) granted accelerated approval to sibeprenlimab (Voyxact), a targeted APRIL inhibitor, for adults with IgAN at risk of disease progression. The phase 3 VISIONARY trial demonstrated its safety and effectiveness, reducing proteinuria by 54.3% and showing promise in disease biomarkers.

   See Also

   Breakthrough Discovery: How Scientists Are Restoring Nerve Function in Diabetes PatientsTattoo Ink and Cancer Risk: What New Research Reveals About Immune ChangesMad Cow Mystery Solved: Uncovering the Real Culprit Behind the Devastating OutbreakNatural Sleep Solutions for Seniors with Dementia: UK Study Reveals Cultural Insights

2. Telitacicept Shines in IgAN Phase 3 Study: Telitacicept, a B-cell modulating biologic, met its primary endpoint in a multicenter study. It significantly reduced 24-hour urine protein-to-creatinine ratio (24h-UPCR) by 58.9% compared to placebo, showcasing its potential as a disease-modifying therapy for high-risk IgAN patients.

3. Atacicept's Role in IgAN Unveiled: Interim results from the ORIGIN-3 trial presented at ASN Kidney Week 2025 revealed atacicept's dual BAFF/APRIL inhibitor action. It led to a 68.3% decrease in galactose-deficient immunoglobulin A1 (Gd-IgA1) and improved hematuria resolution, highlighting its role in the evolving IgAN treatment paradigm.

   See Also

   Cuba's Mosquito-Borne Virus Outbreak: Deaths Surge, Including Children

4. Sparsentan's CV Protection in IgAN: Sparsentan (Filspari), a dual endothelin and angiotensin receptor antagonist, demonstrated rapid proteinuria reductions of around 70% in a 24-week analysis from the SPARTAN study. It also showed favorable trends in blood pressure and cardiovascular biomarkers, supporting its use as first-line therapy in IgAN.

5. MIL62's Success in Membranous Nephropathy: MIL62 achieved complete remission in 49.4% of patients with primary membranous nephropathy (MN) by week 76, compared to just 3.9% with cyclosporine A. This highlights its potential for durable disease control.

6. Tegoprubart's Safer Kidney Transplant Rejection Prevention: The phase 2 BESTOW trial suggests tegoprubart offers similar estimated glomerular filtration rate (eGFR) improvements as tacrolimus while providing a better safety profile. This could revolutionize transplant immunosuppression.

7. Successful Pregnancies Post-Kidney Transplant: Registry analyses from multiple continents indicate successful pregnancy management after kidney transplantation. Maternal, neonatal, and graft outcomes are favorable, emphasizing the need for close clinical surveillance and global data harmonization for high-risk pregnancies.

8. FDA's Orphan Drug Designation for ADPKD: The FDA granted orphan drug designation to ABBV-CLS-628 for autosomal dominant polycystic kidney disease (ADPKD). This early-stage development highlights ongoing efforts to expand treatment options for rare kidney diseases and encourages research into disease-modifying therapies.

These headlines showcase the rapid progress in nephrology, offering hope for improved patient outcomes and a deeper understanding of kidney disease management.